Selective degradation of ARID1B achieved. Earlier this year, Foghorn announced that the company has achieved selective degradation of ARID1B and will provide a program update during 2025.

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), so-called forever chemicals, in drinking water had ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...